ArticleKidney diseases (Basel, Switzerland)
Dihydroquercetin/Taxifolin Inhibits METTL3/m
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There is a close relationship between oxidative stress and renal ischemia-reperfusion injury (RIRI). Dihydroquercetin (DHQ, also known as Taxifolin) can reduce kidney damage, and suppress cellular damage caused by oxidative stress. This study aimed to investigated the effects and underlying mechanisms of DHQ on RIRI. Methods: First, hypoxia/reoxygenation (H/R) treated HK-2 cells were used for RIRI in vitro experiments, and the dosage of DHQ was selected by observing cell viability and lactate dehydrogenase release. The protective effects of DHQ were evaluated by detecting cell apoptosis, reactive oxygen species (ROS) levels, and oxidative stress indicators levels. Results: Our data suggested that DHQ inhibited cell apoptosis, ROS levels, and oxidative stress of H/R treated HK-2 cells. PIM2 regulates cell survival and proliferation, and H/R treatment upregulated PIM2 levels. Over-expression of PIM2 partly reversed the effects of DHQ on protecting HK-2 cells after H/R induction, and promoted RIPK2 phosphorylation mediated NF-κB p65 signaling pathway. Additionally, METTL3 is an N Conclusion: Taken together, DHQ inhibited PIM2 levels by suppressing METTL3 mediated m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.